Novavax Is No Longer Expected To Become Profitable This Year

Novavax cut its full-year guidance in half in early August after reporting a wide second-quarter sales miss. The biotech company now expects $2 billion to $2.3 billion in sales. Novavax remained...

Investors Should Consider Defensive Equities,’ Says JPMorgan; Here Are 2 High-Yield Dividend Names to Consider

The NASDAQ, which has taken the hardest hits this year, is back above 12,200, although still down 22% this year. The S&P 500 has managed to climb back out of the bear market, is above 4,100 now,...

European markets look set to rise after record ECB rate hike

The pan-European Stoxx 600 was up 1.5% in morning trade, with all sectors trading in the green. Basic resources were 4.6% higher, while banks were up 2.4%. The European Central Bank announced a 75...

Citi downgraded a slew of Chinese stocks

Citi's stock analysts reshuffled their top China plays after their downgrades outnumbered upgrades in the latest earnings season. China's "economic recovery looks to be slower than market...

Citi picks China stocks that stand out against a spate of downgrades

Citi's stock analysts reshuffled their top China plays after their downgrades outnumbered upgrades in the latest earnings season. China's "economic recovery looks to be slower than market...

How have stock analysts treated you?

I'm invested in this stock called fortress biotech. They've had a couple positive quarters recently and all the 12 month forecasts and analysts say that it's going to go up somewhere in the range...

UiPath Falls On Lowered Revenue Guidance Amid Currency Pressures

UiPath stock plunged 18.6% to 12.69 just after the opening bell on the stock market today. The software maker reported July-quarter earnings and sales that topped views but lowered its outlook....

J.P. Morgan Says Now Is the Time to Pull the Trigger on Energy Stocks; Here Are 2 Names to Consider

Rising inflation, rising interest rates, and a falling stock market. Looking at the big picture from JPMorgan, Dubravko Lakos-Bujas, the firm’s global head of equity macro research. Energy crisis...

2 “Strong Buy” Stocks From Wall Street’s Best Analyst

The answer to the question, which stock to buy? is no secret, but it is hidden, in the avalanche of data that the markets produce. What’s needed is some clear signal that will cut through the...

Medical Giant Veeva Plummets As A Key Issue Shadows Its Quarterly Beat

Veeva Systems issued light sales guidance for the current quarter and full year. The outlook disappointment comes on the heels on a July-quarter beat. "We are very confident in our competitive...

Pfizer Stock Dives As Covid-Driven Beat Doesn't Translate In Guidance

Pfizer stock tumbled Thursday after delivering a second-quarter earnings beat almost entirely on the back of its Covid vaccine and antiviral pill. The two products, Comirnaty and Paxlovid, brought...

Market Extra: JP Morgan stock analysts show how trendfollowers are making markets more volatile

U.S. stocks have exhibited some strange tendencies since the start of 2022. From hour to hour, stocks aren’t trading like they used to. That’s a marked difference in tone from just two years ago,...

AbbVie Stock Crumbles On Mixed Earnings, Slashes 2022 Earnings Outlook

AbbVie stock crumbled Friday after the drugmaker slashed its 2022 earnings outlook. The company said it incurred an 8-cent per-share charge in the first quarter due to research and development...

Pfizer Stock: With Covid Booster Future Uncertain, Pfizer Digs Into A New Virus

Pfizer will buy privately held RSV treatment-maker ReViral for up to $525 million. The deal bolsters Pfizer's pipeline targeting respiratory syncytial virus. In most people, RSV can cause...

Twilio Stock Surges As Revenue Blows Past Estimates Amid Acquisition Spree

Twilio (TWLO) shares jumped 11.7% to 225.75 in morning trading on the stock market today. The San Francisco-based company reported earnings after the market close on Wednesday. Twilio said it lost...

With Omicron, Stock Analysts Expecting More Uncertainty

Stocks rose on Monday, but analysts expect a bumpy ride for share prices while experts assess whether existing vaccines will be effective against the new variant.

Why Biohaven Stock Crumbled On This Premium Deal With Pfizer

Biohaven's Nurtec ODT is the only orally disintegrating tablet to treat or prevent acute migraines. Pfizer will sell it outside the U.S. In exchange, Biohaven will receive a tiered double-digit...

One-Stop Business News backed by Mark Cuban. Free to Use →